LitAlert ~~ GeneLit.com

    • Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
    • Nishikawa G, Booth C, Prasad V.
    • Cancer. 2020 May 27. doi: 10.1002/cncr.32979. [Epub ahead of print]
    • Commentary
    • PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
    • Gonçalves A, Bertucci A, Bertucci F.
    • Cancers (Basel). 2020 May 27;12(65):E1378. doi: 10.3390/cancers12061378.
    • Wise Management of Ovarian Cancer: On the Cutting Edge.
    • Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • J Pers Med. 2020 May 21;10(2):E41. doi: 10.3390/jpm10020041.
    • Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
    • Vikas P, Borcherding N, Chennamadhavuni A, Garje R.
    • Front Oncol. 2020 Apr 28;10:570. doi: 10.3389/fonc.2020.00570.